Physician profile
Timothy J Wright
NPI 1164512240
$3,580.45
in general payments reported to CMS, 2019-2025
31 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $802 · 2022: $1,742 · 2023: $932 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,037.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,036.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $464.94 | 2021-2023 | |
| Novo Nordisk INC | $446.29 | 2021-2023 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $334.09 | 2021-2023 | Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company Ltd. | $298.29 | 2022 | |
| Lilly USA, LLC | $295.65 | 2021-2023 | Mounjaro, Emgality, Reyvow |
| Takeda Pharmaceuticals U.S.A., INC. | $227.60 | 2021-2023 | Trintellix |
| Corcept Therapeutics | $206.22 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $187.63 | 2021-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.81 | 2021-2023 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $152.63 | 2021 | |
| Antares Pharma, INC. | $117.30 | 2021-2023 | Xyosted, Nocdurna, Tlando |
| Optinose US, INC. | $72.20 | 2021-2023 | |
| Idorsia Pharmaceuticals US INC | $56.45 | 2022-2023 | Quviviq |
| Amgen INC. | $53.77 | 2022-2023 | Repatha, Otezla |
| Amarin Pharma, INC. | $52.90 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $49.05 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Mylan Specialty L.P. | $45.06 | 2022-2023 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $40.72 | 2022 | |
| Eisai INC. | $38.74 | 2021 | |
| Merck Sharp & Dohme LLC | $31.84 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $31.70 | 2021-2022 | |
| Boston Scientific Corporation | $31.18 | 2025 | General - Pain Management |
| Halozyme INC | $24.91 | 2023 | |
| Gilead Sciences, INC. | $24.79 | 2025 | |
| Scilex Pharmaceuticals INC. | $22.99 | 2023 | Ztlido |
| Cranial Technologies, INC | $20.13 | 2023 | Doc Band |
| Baxter Healthcare | $18.65 | 2023 | Hillrom - Life 2000 Ventilation System |
| Daiichi Sankyo INC. | $18.50 | 2022 | |
| Arbor Pharmaceuticals, INC. | $15.04 | 2021 | |
| Organon LLC | $10.39 | 2022 | |
| Genentech USA, INC. | $8.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.